CTIS2023-505844-21-00招募中1 期
An open-label, multiple dose, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of filgotinib in children and adolescents from 8 to less than 18 years of age with juvenile idiopathic arthritis - GLPG-0634-CL-131
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Galapagos
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Subject and/or parent(s)/legal guardian must be able and willing to comply with the CSP requirements and must sign and date the informed consent form as approved by the IEC/IRB and as described in Section 12.7.2, prior to any screening evaluations., Subject with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts, Appendix 3). Subject must have a minimum weight of 15 kg., Subject must be able and willing to comply with restrictions on prior and concomitant medication (as described in Section 6.3.2)., Subject must meet the ILAR classification for 1 of the following categories and have, according to the investigator’s judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy. a. RF-positive polyarthritis b. RF-negative polyarthritis c. Oligoarthritis d. Psoriatic arthritis e. ERA Note: Historical HLA-B27 results are considered appropriate for ERA diagnosis during screening. f. sJIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment, Subject with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and bDMARDs (including MTX) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis., Female or male subjects from 8 to <18 years of age, on the date of signing the informed consent form (ICF)., Female subjects of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test., Female subject of childbearing potential who are, in the opinion of the investigator, potentially sexually active and at risk for pregnancy, must agree to use contraception/preventive exposure measures (as described in Section 6.3.1.1.2)., Female subject of non-childbearing potential must meet the definition in Section 6.3.1.1.1.
排除标准
- •Subject with persistent oligoarthritis., Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria)., Subject presenting any signs or symptoms of SARS-Cov-2 infection, as detected at baseline following careful physical examination (e.g. cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, etc.) (BMJ, 2020a, 2020b), should undergo testing, even if fully vaccinated against SARS-CoV-2, as per locally applicable standard criteria to diagnose SARS-CoV-2 infection, and be excluded if positive., Subject has a history of malignancy or myelo- or lymphoproliferative disorder prior to screening., Subject has a history or presence of clinically significant abnormalities detected on 12-lead electrocardiogram (ECG) of either rhythm or conduction e.g. known long QT syndrome or a QTcF >450 ms detected on the 12-lead ECG. A first-degree atrioventricular block will not be considered as a significant abnormality., Subject has any other condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g. compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments., Subject with a history of macrophage activation syndrome within 6 months prior to the screening visit., Subject with psychological or cognitive difficulties that might interfere with study participation., Subject for whom results of the following laboratory tests performed at the central laboratory at screening meet any of the criteria below: a. Hemoglobin <8.0 g/dL (SI: <80 g/L) b. Neutrophils <1.05 x 10 3 3 cells/mm (SI: <1.05 x 10 9 cells/L) c. Lymphocytes <0.5 x 10 3 3 cells/mm (SI: <0.5 x 10 9 cells/L) d. ALT or AST >=1.5x ULN e. Total bilirubin level >=2x ULN unlessor >=3x ULN if the subject has been diagnosed with Gilbert's disease and this is clearly documented f. CrCl <60 mL/min/1.73 m 2 by the revised bedside Schwartz equation, Subject has taken any prohibited therapies within the defined washout periods before the planned first dose of IP., Subject concurrently participates or participated in a drug, drug/device or biologic investigational research study within 4 weeks or 5 half-lives of the IP, whichever is longer, prior to the first dose., Subject with undifferentiated arthritis., Subject has a known hypersensitivity to IP ingredients or history of a significant allergic reaction to IP ingredients as determined by the investigator., Female subject is pregnant or breast feeding or intending to become pregnant or breastfeed during the study., Investigator or other study staff or relative thereof who is directly involved in the conduct of the study., Subject has any condition or circumstances that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements (e.g. active alcohol or drug abuse)., Subject has a history of chronic alcohol abuse, intravenous drug abuse, or other illicit drug abuse within the 2 years prior to screening., Subject is institutionalized by virtue of an order issued by either the judicial or the administrative authorities or has a dependence on the sponsor or investigator., Subject with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis
研究者
相似试验
进行中（未招募）
不适用
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.Anemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysisMedDRA version: 17.0Level: LLTClassification code 10058124Term: Nephrogenic anemiaSystem Organ Class: 100000004851EUCTR2007-007758-70-HUF. Hoffmann-La Roche Ltd68
进行中（未招募）
1 期
An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA® for maintenance treatment of anemia in pediatric patients with chronic kidney disease on hemodialysisAnemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysisMedDRA version: 9.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaEUCTR2007-007758-70-FRF. Hoffmann-La Roche Ltd41
进行中（未招募）
不适用
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.Anemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysisMedDRA version: 17.0Level: LLTClassification code 10058124Term: Nephrogenic anemiaSystem Organ Class: 100000004851EUCTR2007-007758-70-DEF. Hoffmann-La Roche Ltd68
进行中（未招募）
不适用
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.Anemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysisMedDRA version: 14.1Level: LLTClassification code 10058124Term: Nephrogenic anemiaSystem Organ Class: 100000004851EUCTR2007-007758-70-BEF. Hoffmann-La Roche Ltd68
进行中（未招募）
1 期
An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA for maintenance treatment of anemia in pediatric patients with chronic kidney disease on hemodialysisChronic renal anemiaMedDRA version: 14.1Level: LLTClassification code 10058123Term: Renal anaemiaSystem Organ Class: 100000004851EUCTR2007-007758-70-ITROCHE41